2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-111162
    GSK494581A 909416-67-7 98%
    GSK494581A is a specific ligand for human GPR55 (pEC50 of 6.8) and also acts as an inhibitor of glycine transporter subtype 1 (GlyT1). GSK494581A may regulate pain signaling, bone morphogenesis, and vascular endothelial cell formation by binding to GPR55.
    GSK494581A
  • HY-111273
    AR244555 858350-62-6 98%
    AR244555 is a malate-aspartate shuttle (MAS) inverse agonist with IC50s of 186 nM and 348 nM in human and rat inositol phosphatase (IP) Gq coupling assays respectively. AR244555 has cardioprotective effects.
    AR244555
  • HY-111587
    Ifenprodil glucuronide 66516-92-5 98%
    Ifenprodil glucuronide is a derivative of Ifenprodil. Ifenprodil is a vasodilator and an inhibitor of platelet aggregation, and Ifenprodil glucuronide has no effect on platelet aggregation and arterial contraction.
    Ifenprodil glucuronide
  • HY-112461
    NF449 389142-38-5 98%
    NF449 is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 is a Gsα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs.
    NF449
  • HY-112817
    8-Oxo-dGTP 139307-94-1 98%
    8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms.
    8-Oxo-dGTP
  • HY-112865
    Octocog alfa 139076-62-3 98%
    Octocog alfa (ADVATE; BAY 81-8973; Kovaltry) is a standard half-length recombinant coagulation factor FVIII replacement therapy that also functions as a thrombin generation modulator. Octocog alfa regulates thrombin generation-related parameters in vitro and is used in studies related to severe hemophilia A.
    Octocog alfa
  • HY-112885
    nor-NOHA 189302-40-7 98%
    nor-NOHA is a selective and reversible arginase inhibitor. nor-NOHA induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA has anti-leukemic activity. nor-NOHA can used in study of endothelial dysfunction, immunosuppression and metabolism.
    nor-NOHA
  • HY-113043
    Galactonic acid 13382-27-9 98%
    Galactonic acid is a metabolite of Galactose. Galactose is converted into Galactonic acid in vivo. Galactonic acid can be used in galactosemia research.
    Galactonic acid
  • HY-113635
    ONO-6240 99659-62-8 98%
    ONO-6240 is a platelet-activating factor antagonist. ONO-6240 prevents EOS infiltration into airway. ONO-6240 can be used in the study of asthmatic.
    ONO-6240
  • HY-113723
    MRS2298 491611-43-9 98%
    MRS2298? is a potent acyclic P2Y1 receptor antagonist with a Ki of 29.6 nM. MRS2298 inhibits the ADP-induced aggregation of human platelets with an IC50 of 62.8 nM. MRS2298 inhibits Ca2+ rise in platelets with an IC50 of 810 nM.
    MRS2298
  • HY-113748
    Rev 6207 free base 98056-23-6 98%
    Rev 6207 (free base) is a potent non-thiol angiotensin I converting enzyme inhibitor. Rev 6207 (free base) has comparable antihypertensive activity to Enalapril (HY-B0331) in awake monkeys with high renin activity and can be used in the study of hypertensive diseases.
    Rev 6207 free base
  • HY-113813
    SQ 28853 107550-68-5 98%
    SQ 28853 is an angiotensin converting enzyme (ACE) inhibitor with potent diuretic activity. SQ 28853 can be used for the research of cardiovascular.
    SQ 28853
  • HY-113892
    Leniquinsin 10351-50-5 98%
    Leniquinsin is a phosphodiesterase inhibitor, which is used as a vasodilator.
    Leniquinsin
  • HY-114638
    Diproteverine 69373-95-1 98%
    Diproteverine (BRL 40015) is an oral activity calcium channel blocker. Diproteverine embryonic toxicity. Diproteverine also shows antianginal properties.
    Diproteverine
  • HY-114674
    A-127722 195704-72-4 98%
    A-127722 is A 2, 4-dialarylpyrrolidine-3-carboxylic acid ETA selective endothelin receptor (ET receptor) antagonist with IC50 value of 0.36 nM.
    A-127722
  • HY-114686
    (R)-γ-Valerolactone 58917-25-2
    (R)-γ-Valerolactone is a precursor of antihypertensive compounds. (R)-γ-Valerolactone can also be used in the research of biodegradable plastics and biofuels.
    (R)-γ-Valerolactone
  • HY-114846
    Ro 22-9194 106134-33-2 98%
    Ro 22-9194 inhibits aggregation and thromboxane Az (TXA2) synthetase activity in rabbit and human platelets. Ro 22-9194 has a potent inhibitory action against various types of model arrhythmias. Ro 22-9194 has non-cholinergic cardiac depressant properties with its vasodilating action.
    Ro 22-9194
  • HY-114941
    Aladotril 173429-64-6 98%
    Aladotril (BP1137) is the inhibitor for neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), that ameliorates the cardiac hypertrophy in rats, without decreasing the blood pressure. Aladotril can be used in research about heart failure and cardiac remodeling after myocardial infarction.
    Aladotril
  • HY-114942
    Prostaglandin E1 ethyl ester 35900-16-4 98%
    Prostaglandin E1 ethyl ester (Prostaglandin E1 Et ester) is the esterified form of Prostaglandin E1 (PGE1; HY-B0131). Prostaglandin E1 (Alprostadil) is a prostaglandin receptor ligand that induces vasodilation and inhibits platelet aggregation.
    Prostaglandin E1 ethyl ester
  • HY-115014
    Cibenzoline succinate 100678-32-8 98%
    Cibenzoline succinate (Cifenline succinate) is the succinate form of Cibenzoline (HY-106577). Cibenzoline succinate is an inhibitor for ATP-sensitive potassium (KATP) channel by affecting the pore-forming Kir6.2 subunit with IC50 of 22.2 µM. Cibenzoline succinate affects insulin secretion and exhibits antiarrhythmic and antidiabetic activities.
    Cibenzoline succinate
Cat. No. Product Name / Synonyms Application Reactivity